Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

89.88 +1.00 (+1.13%)
Streaming Delayed Price Updated: 2:39 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
News headline image
Why BioNTech Stock Jumped by Nearly 4% on Wednesday ↗
The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity. 
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
News headline image
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
Why BioNTech Stock Bumped Higher Today ↗
Investors were cheered by two pieces of good news concerning the biotech's most famous product. 
Via The Motley Fool
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside ↗
Via Stocktwits
News headline image
What Analysts Are Saying About BioNTech Stock ↗
 
Via Benzinga
Why Did BioNTech Stock Surge 10% Pre-Market Today? ↗
Via Stocktwits
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population ↗
Via Stocktwits
News headline image
CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids ↗
Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines. 
Via Investor's Business Daily
News headline image
The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut ↗
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters. 
Via Investor's Business Daily
Topics Government
News headline image
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax ↗
Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults. 
Via Benzinga
News headline image
Oracle Retreats, Fed Rate Cut Looms, and Vaccine Politics Shake Pharma Stocks ↗
Markets closed Friday in mixed fashion as economic uncertainty and politics clashed with earnings optimism. Oracle's rollercoaster continues, RFK Jr. rattles vaccine makers, and the Fed appears poised... 
Via Chartmill
Topics Artificial Intelligence Economy
News headline image
Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio? ↗
Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others. 
Via Benzinga
Topics Earnings
News headline image
Why BioNTech Stock Sank by More Than 7% Today ↗
The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future.. 
Via The Motley Fool
Topics Death Government
News headline image
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths ↗
Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths. 
Via Benzinga
Topics Government
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults ↗
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported. 
Via Benzinga
News headline image
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy ↗
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates. 
Via Benzinga
News headline image
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
From BioNTech SE
Via GlobeNewswire
News headline image
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer. 
Via Investor's Business Daily
News headline image
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
News headline image
Why BioNTech Stock Crushed the Market Today ↗
The company might be close to commercializing its most advanced pipeline program. 
Via The Motley Fool
News headline image
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.? ↗
It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure. 
Via Investor's Business Daily
News headline image
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb ↗
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study. 
Via Investor's Business Daily
News headline image
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data ↗
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China. 
Via Benzinga
News headline image
Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works ↗
Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest. 
Via Benzinga
News headline image
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio? ↗
Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades. 
Via Benzinga
News headline image
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines ↗
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing. 
Via Benzinga
News headline image
RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles. ↗
Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.